Galderma Group AG - SIC # 2840 -

Ticker Exchange SIC # Website Latest Ticker
GALDY Over the counter 2840 www.galderma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galderma Group AG

Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis - Nov 28th, 2024 6:00 am
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation - Nov 4th, 2024 6:00 am
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends - Oct 25th, 2024 5:00 am
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance - Oct 24th, 2024 5:00 am
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) - Oct 21st, 2024 5:00 am
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024 - Sep 17th, 2024 5:00 am
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis - Aug 13th, 2024 5:01 am
Galderma to pursue a new scientific partnership with L’Oréal to further advance its category leadership in dermatology - Aug 5th, 2024 5:20 am
Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe - Jul 30th, 2024 5:00 am
Galderma Delivers Record Net Sales of 2.2 Billion USD and 10.8% Year-on-Year Growth at Constant Currency for the First Half of 2024 - Jul 25th, 2024 5:00 am
PHASE III ARCADIA 1 and 2 Trial Primary Results Published in The Lancet: Galderma’s Nemolizumab Improves Key Aspects of Atopic Dermatitis – Itch, Skin Lesions and Sleep Disturbance - Jul 25th, 2024 4:30 am
Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries - May 7th, 2024 5:00 am